Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy

Bakakos, Agamemnon; Rovina, Nikoletta; Bakakos, Petros

doi:10.3390/ijms22083969

Cited by 19 publications

(9 citation statements)

References 65 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Benralizumab combats the effect of over-activated IL-5 function by targeting the IL-5 receptor. It not only inhibits the function of the IL-5 receptor, but it can also direct the apoptosis process in eosinophils and basophils by recruiting NK cells [59]. Benralizumab application improved all patients' situations at three months and six months treatment in a recently published multicenter study involving 42 patients.…”

Section: The Application Of Monoclonal Antibodies In Patients With T2...mentioning

confidence: 99%

A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease

Song

2022

Life

View full text Add to dashboard Cite

Antibodies are a type of protein produced by active B cells in response to antigen stimulation. A series of monoclonal antibodies and neutralizing antibodies have been invented and put into clinical use because of their high therapeutic effect and bright developing insight. Patients with cancer, infectious diseases, and autoimmune diseases can all benefit from antibody therapy. However, the targeting aspects and potential mechanisms for treating these diseases differ. In the treatment of patients with infectious diseases such as COVID-19, neutralizing antibodies have been proposed as reliable vaccines against COVID-19, which target the ACE2 protein by preventing virus entry into somatic cells. Monoclonal antibodies can target immune checkpoints (e.g., PD-L1 and CTLA-4), tyrosine kinase and subsequent signaling pathways (e.g., VEGF), and cytokines in cancer patients (e.g. IL-6 and IL-1β). It is debatable whether there is any connection between the use of antibodies in these diseases. It would be fantastic to discover the related points and explain the burden for the limitation of cross-use of these techniques. In this review, we provided a comprehensive overview of the use of antibodies in the treatment of infectious disease and cancer patients. There are also discussions of their mechanisms and history. In addition, we discussed our future outlook on the use of antibodies.

show abstract

Section: The Application Of Monoclonal Antibodies In Patients With T2...mentioning

confidence: 99%

A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease

Song

2022

Life

View full text Add to dashboard Cite

show abstract

“…Benralizumab has found to deplete peripheral blood basophils [ 114 ]. Oral corticosteroid use was also reduced with mepolizumab or benralizumab in comparison with placebo [ 19 , 27 , 30 , 105 , 113 , 114 , 115 , 116 , 117 ]. Despite their comparable effects, anti-IL-5 and anti-IL-5Rs have different mechanisms of action, and their effects vary depending on specific asthma endotypes.…”

Section: Biologic Agents Targeting Type 2 Inflammationmentioning

confidence: 99%

Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice

Porpodis

Tsiouprou

Apostolopoulos

et al. 2022

JPM

View full text Add to dashboard Cite

Asthma phenotyping and endotyping are constantly evolving. Currently, several biologic agents have been developed towards a personalized approach to asthma management. This review will focus on different eosinophilic phenotypes and Th2-associated endotypes with eosinophilic inflammation. Additionally, airway remodeling is analyzed as a key feature of asthmatic eosinophilic endotypes. In addition, evidence of biomarkers is examined with a predictive value to identify patients with severe, uncontrolled asthma who may benefit from new treatment options. Finally, there will be a discussion on the results from clinical trials regarding severe eosinophilic asthma and how the inhibition of the eosinophilic pathway by targeted treatments has led to the reduction of recurrent exacerbations.

show abstract

“…Lung eosinophilia induces severe asthma by promoting IL-5 signaling. Recent clinical progress has been made by the discovery of biological agents targeting IL-5/IL-5R, such as Mepolizumab, Benralizumab, and Reslizumab [56]. Randomized control studies (RCTs) revealed the efficacy of these agents against severe eosinophilic asthma [57][58][59].…”

Section: Type 2 Immune Responses In Arthritismentioning

confidence: 99%

Inflammatory Arthritis and Bone Metabolism Regulated by Type 2 Innate and Adaptive Immunity

Omata

Frech

Saito

et al. 2022

IJMS

View full text Add to dashboard Cite

While type 2 immunity has traditionally been associated with the control of parasitic infections and allergic reactions, increasing evidence suggests that type 2 immunity exerts regulatory functions on inflammatory diseases such as arthritis, and also on bone homeostasis. This review summarizes the current evidence of the regulatory role of type 2 immunity in arthritis and bone. Key type 2 cytokines, like interleukin (IL)-4 and IL-13, but also others such as IL-5, IL-9, IL-25, and IL-33, exert regulatory properties on arthritis, dampening inflammation and inducing resolution of joint swelling. Furthermore, these cytokines share anti-osteoclastogenic properties and thereby reduce bone resorption and protect bone. Cellular effectors of this action are both T cells (i.e., Th2 and Th9 cells), but also non-T cells, like type 2 innate lymphoid cells (ILC2). Key regulatory actions mediated by type 2 cytokines and immune cells on both inflammation as well as bone homeostasis are discussed.

show abstract

Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy

Cited by 19 publications

References 65 publications

A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease

A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease

Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice

Inflammatory Arthritis and Bone Metabolism Regulated by Type 2 Innate and Adaptive Immunity

Contact Info

Product

Resources

About